2011
Effects of Risperidone and Parent Training on Adaptive Functioning in Children With Pervasive Developmental Disorders and Serious Behavioral Problems
Scahill L, McDougle CJ, Aman MG, Johnson C, Handen B, Bearss K, Dziura J, Butter E, Swiezy NG, Arnold LE, Stigler KA, Sukhodolsky DD, Lecavalier L, Pozdol SL, Nikolov R, Hollway JA, Korzekwa P, Gavaletz A, Kohn AE, Koenig K, Grinnon S, Mulick JA, Yu S, Vitiello B, Network R. Effects of Risperidone and Parent Training on Adaptive Functioning in Children With Pervasive Developmental Disorders and Serious Behavioral Problems. Journal Of The American Academy Of Child & Adolescent Psychiatry 2011, 51: 136-146. PMID: 22265360, PMCID: PMC3941712, DOI: 10.1016/j.jaac.2011.11.010.Peer-Reviewed Original ResearchAdaptation, PsychologicalAdolescentAntipsychotic AgentsAsperger SyndromeAutistic DisorderChecklistChildChild Behavior DisordersChild Development Disorders, PervasiveChild, PreschoolCombined Modality TherapyCommunicationCooperative BehaviorDose-Response Relationship, DrugEducationFemaleHumansMaleRisperidoneSocialization
2008
Cognitive Effects of Risperidone in Children with Autism and Irritable Behavior
Aman MG, Hollway JA, McDougle CJ, Scahill L, Tierney E, McCracken JT, Arnold LE, Vitiello B, Ritz L, Gavaletz A, Cronin P, Swiezy N, Wheeler C, Koenig K, Ghuman JK, Posey DJ. Cognitive Effects of Risperidone in Children with Autism and Irritable Behavior. Journal Of Child And Adolescent Psychopharmacology 2008, 18: 227-236. PMID: 18582177, PMCID: PMC2935828, DOI: 10.1089/cap.2007.0133.Peer-Reviewed Original ResearchConceptsSevere behavioral disturbancesVerbal learning taskSpatial memory taskIrritable behaviorPurdue pegboard taskDouble-blind placebo-controlled parallel group designBehavioral disturbancesPlacebo-controlled parallel-group designMemory taskCognitive processesVerbal learningCognitive tasksMental ageSustained attentionHand-eye coordinationCognitive effectsCognitive performanceCancellation taskLearning taskSpatial memoryCognitive partDependent measuresPegboard taskAutismClassroom tasks
2007
Psychopharmacology
Scahill L, Koenig K, Carroll DH, Pachler M. Psychopharmacology. Journal Of Child And Adolescent Psychiatric Nursing 2007, 20: 188-190. PMID: 17688557, DOI: 10.1111/j.1744-6171.2007.00112.x.Peer-Reviewed Original Research
2006
Educational Placements and Service Use Patterns of Individuals with Autism Spectrum Disorders
White SW, Scahill L, Klin A, Koenig K, Volkmar FR. Educational Placements and Service Use Patterns of Individuals with Autism Spectrum Disorders. Journal Of Autism And Developmental Disorders 2006, 37: 1403-1412. PMID: 17082975, DOI: 10.1007/s10803-006-0281-0.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAsperger SyndromeAutistic DisorderChildChild Development Disorders, PervasiveCommunicationEducation, SpecialFemaleFollow-Up StudiesHumansIntelligenceLanguage Development DisordersLanguage TherapyMainstreaming, EducationMaleSocial BehaviorSpeech TherapyStatistics as TopicUtilization ReviewVirginiaConceptsEducational placementAutism spectrum disorderSpectrum disorderChild characteristicsMajority of studentsHigh-functioning childrenLower cognitive abilityCertain child characteristicsSpecial educationMost studentsFirst gradeCommunication skillsSpecial servicesStudentsLess emphasisSame placementSchoolsEducationSkillsDisordersService use patternsEmphasisPlacementGradeChildrenValidity of the Autism Diagnostic Interview-Revised
Lecavalier L, Aman MG, Scahill L, McDougle CJ, McCracken JT, Vitiello B, Tierney E, Arnold LE, Ghuman JK, Loftin RL, Cronin P, Koenig K, Posey DJ, Martin A, Hollway J, Lee LS, Kau AS. Validity of the Autism Diagnostic Interview-Revised. American Journal On Intellectual And Developmental Disabilities 2006, 111: 199-215. PMID: 16597187, DOI: 10.1352/0895-8017(2006)111[199:votadi]2.0.co;2.Peer-Reviewed Original Research
2005
Assessment of the Integrity of Study Blindness in a Pediatric Clinical Trial of Risperidone
Vitiello B, Davies M, Arnold L, McDougle C, Aman M, McCracken J, Scahill L, Tierney E, Posey D, Swiezy N, Koenig K. Assessment of the Integrity of Study Blindness in a Pediatric Clinical Trial of Risperidone. Journal Of Clinical Psychopharmacology 2005, 25: 565-569. PMID: 16282839, DOI: 10.1097/01.jcp.0000185426.08268.92.Peer-Reviewed Original ResearchConceptsPlacebo treatment armsClinical evaluatorsAdverse eventsClinical trialsTreatment assignmentTreatment armsActual treatment assignmentPlacebo-controlled trialPediatric clinical trialsAdverse event dataLack of improvementActive treatmentOutcome dataPediatric psychopharmacologyIndividual treatment assignmentRisperidoneTrialsBlindnessParentsArmAutismAcute and Long-Term Safety and Tolerability of Risperidone in Children with Autism
Aman MG, Arnold M, McDougle CJ, Vitiello B, Scahill L, Davies M, McCracken JT, Tierney E, Nash PL, Posey DJ, Chuang S, Martin A, Shah B, Gonzalez NM, Swiezy NB, Ritz L, Koenig K, McGough J, Ghuman JK, Lindsay RL. Acute and Long-Term Safety and Tolerability of Risperidone in Children with Autism. Journal Of Child And Adolescent Psychopharmacology 2005, 15: 869-884. PMID: 16379507, DOI: 10.1089/cap.2005.15.869.Peer-Reviewed Original ResearchConceptsSimpson-Angus Neurological Rating ScaleAbnormal Involuntary Movement ScaleAdverse eventsBody mass indexAcute trialTreatment-emergent adverse eventsTolerability of risperidoneCommon adverse eventsMost adverse eventsOpen-label extensionPlacebo-controlled trialMonths of treatmentUnanticipated adverse eventsSame adverse eventsLong-term safetyNeurological Rating ScaleOpen-label risperidoneRisperidone groupRisperidone therapyExtrapyramidal symptomsBlood assessmentMass indexPlacebo nonrespondersMovement ScaleLifetime diagnosis
2003
Parent-Defined Target Symptoms Respond to Risperidone in RUPP Autism Study: Customer Approach to Clinical Trials
ARNOLD L, VITIELLO B, MCDOUGLE C, SCAHILL L, SHAH B, GONZALEZ N, CHUANG S, DAVIES M, HOLLWAY J, AMAN M, CRONIN P, KOENIG K, KOHN A, MCMAHON D, TIERNEY E. Parent-Defined Target Symptoms Respond to Risperidone in RUPP Autism Study: Customer Approach to Clinical Trials. Journal Of The American Academy Of Child & Adolescent Psychiatry 2003, 42: 1443-1450. PMID: 14627879, DOI: 10.1097/00004583-200312000-00011.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAffectAggressionAutistic DisorderChildClinical Trials as TopicDopamine AntagonistsDouble-Blind MethodEndpoint DeterminationFemaleHumansMaleObserver VariationParent-Child RelationsPlacebosResearch DesignRisperidoneSeverity of Illness IndexStereotyped BehaviorTreatment OutcomeConceptsAberrant Behavior Checklist-Irritability subscaleClinical trialsIrritability subscaleClinical Global Impression-ImprovementDouble-blind trialPediatric Psychopharmacology Autism NetworkChief complaintCommon symptomsTarget symptomsEfficacy assessmentIrritable behaviorSymptom categoriesRisperidoneChange scoresSymptomsEffect size dInterrater reliabilityTrialsPlaceboTreatment effectsClinical applicationPrimary measureConsumer-friendly wayWeeksAutism Network
2002
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D. Risperidone in Children with Autism and Serious Behavioral Problems. New England Journal Of Medicine 2002, 347: 314-321. PMID: 12151468, DOI: 10.1056/nejmoa013171.Peer-Reviewed Original ResearchConceptsClinical Global Impression-ImprovementAtypical antipsychotic agentsPlacebo groupSelf-injurious behaviorRisperidone groupAntipsychotic agentsAutistic disorderIrritability scoresDouble-blind trialPrimary outcome measureTreatment of adultsTraditional antipsychotic medicationsPercent decreaseSerious behavioral disturbancesAberrant Behavior ChecklistRisperidone therapyTardive dyskinesiaAntipsychotic medicationAverage weight gainOutcome measuresPositive responsePostsynaptic dopamineSerotonin receptorsBehavioral disturbancesSevere tantrums
2001
Methodological Issues in Designing a Multisite Trial of Risperidone in Children and Adolescents with Autism
Scahill L, McCracken J, McDougle C, Aman M, Arnold L, Tierney E, Cronin P, Davies M, Ghuman J, Gonzalez N, Koenig K, Lindsay R, Martin A, McGough J, Posey D, Swiezy N, Volkmar F, Ritz L, Vitiello B. Methodological Issues in Designing a Multisite Trial of Risperidone in Children and Adolescents with Autism. Journal Of Child And Adolescent Psychopharmacology 2001, 11: 377-388. PMID: 11838820, DOI: 10.1089/104454601317261555.Peer-Reviewed Original ResearchConceptsPlacebo-controlled studyPlacebo-controlled discontinuation studyAutistic disorderSafety of risperidoneStudy of RisperidoneStandard pharmacological treatmentSelf-injurious behaviorDiscontinuation studyPharmacological treatmentClinical trialsInclusion criteriaLong-term effectsSevere tantrumsTrial designClinical relevanceClinical practiceLength of trialRisperidoneMultisite trialStudy designContinuous treatmentTrialsTreatment effectsDisordersMaintenance phaseAssessment of Children With Pervasive Developmental Disorders
Koenig K, Scahill L. Assessment of Children With Pervasive Developmental Disorders. Journal Of Child And Adolescent Psychiatric Nursing 2001, 14: 159-166. PMID: 11767506, DOI: 10.1111/j.1744-6171.2001.tb00309.x.Peer-Reviewed Original ResearchConceptsAdvanced practice nursesPervasive developmental disorderDevelopmental disordersChildhood psychiatric disordersGroup of conditionsPractice nursesAssessment of childrenAppropriate diagnosisPsychiatric disordersClinical experienceCounseling parentsDisordersFurther consultationInterventionCurrent literatureDiagnosisCommunication deficitsDiagnostic instrumentRepetitive behaviorsChildrenNormal growthFormal trainingNursesParents
1999
Pharmacotherapy in Children and Adolescents With Pervasive Developmental Disorders
Scahill L, Koenig K. Pharmacotherapy in Children and Adolescents With Pervasive Developmental Disorders. Journal Of Child And Adolescent Psychiatric Nursing 1999, 12: 41-43. PMID: 10347430, DOI: 10.1111/j.1744-6171.1999.tb00040.x.Peer-Reviewed Original ResearchConceptsSide effectsNeuroleptic medicationAtypical neurolepticsLong-term side effectsNewer atypical neurolepticsRecurrent side effectsSerotonin reuptake inhibitorsExtrapyramidal side effectsUntoward side effectsLowest possible doseCourse of treatmentTreatment of childrenSevere behavioral difficultiesSelf-injurious behaviorMedication withdrawalReuptake inhibitorsMedication doseClinical benefitTraditional neurolepticsAbnormal movementsPossible doseTreatment planBaseline measurementsDepressed moodWeight gainOpen-Label Quetiapine in the Treatment of Children and Adolescents with Autistic Disorder
Martin A, Koenig K, Scahill L, Bregman J. Open-Label Quetiapine in the Treatment of Children and Adolescents with Autistic Disorder. Journal Of Child And Adolescent Psychopharmacology 1999, 9: 99-107. PMID: 10461820, DOI: 10.1089/cap.1999.9.99.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntipsychotic AgentsAutistic DisorderChildDibenzothiazepinesHumansMaleProspective StudiesQuetiapine FumarateWeight GainConceptsClinical Global Impression ScaleTreatment of childrenSide effectsAutistic disorderOpen-label trialShort-term safetyWeeks of treatmentGlobal Impression ScaleGlobal improvement itemSignificant side effectsSerious side effectsDSM-IV criteriaFurther dose increasesLack of responseMean ageImpression ScalePossible seizuresMale subjectsWeight gainBehavioral activationFourth weekQuetiapine fumarateDose increaseClinical populationsWeeks